Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 77-89 http://medscipublisher.com/index.php/cge 87 Cheng Y., He C., Wang M.N., Ma X., Mo F., Yang S.Y., Han J.H., and Wei X., 2019, Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials, Signal Transduction and Targeted Therapy, 4(1): 62. https://doi.org/10.1038/s41392-019-0095-0 Chen S.Y., 2024, Optimizing drug therapy using genomic information: a pathway to personalized medicine, International Journal of Molecular Medical Science, 14(1): 61-68 https://doi.org/10.5376/ijmms.2024.14.0009 Chiam K., Ricciardelli C., and Bianco-Miotto T., 2014, Epigenetic biomarkers in prostate cancer: current and future uses, Cancer Letters, 342(2): 248-256. https://doi.org/10.1016/j.canlet.2012.02.011 Chin S.P., Dickinson J.L., and Holloway A.P., 2011, Epigenetic regulation of prostate cancer, Clinical Epigenetics, 2(2): 151-169. https://doi.org/10.1007/s13148-011-0041-7 Clancy K., Russell A., Subramanian V., Nguyen H., Qian Y., Campbell R., and Thompson P., 2017, Citrullination/methylation crosstalk on histone H3 regulates ER-target gene transcription, ACS Chemical Biology, 12(6): 1691-1702. https://doi.org/10.1021/acschembio.7b00241 Conteduca V., Hess J., Yamada Y., Ku S., and Beltran H., 2021, Epigenetics in prostate cancer: clinical implications, Translational Andrology and Urology, 10(7): 3104-3116. https://doi.org/10.21037/TAU-20-1339 Dobosy J.R., Roberts J.L.W., Fu V.X., and Jarrard D.F., 2007, The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia, The Journal of Urology, 177(3): 822-831. https://doi.org/10.1016/J.JURO.2006.10.063 Dorna D., Grabowska A., and Paluszczak J., 2023, Natural products modulating epigenetic mechanisms by affecting histone methylation/demethylation: targeting cancer cells, British Journal of Pharmacology, 182(10): 2137-2158. https://doi.org/10.1111/bph.16237 Das Pramanik S., Halder A., Mukherjee U., Kumar D., Dey Y.N., and Mogana R., 2022, Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer, Frontiers in Chemistry, 10: 948217. https://doi.org/10.3389/fchem.2022.948217 Ellinger J., Kahl P., von der Gathen J., Rogenhofer S., Heukamp L.C., Gütgemann I., Walter B., Hofstadter F., Büttner R., Müller S., Bastian P.J., and von Ruecker A., 2010, Global levels of histone modifications predict prostate cancer recurrence, The Prostate, 70(1): 61-69. https://doi.org/10.1002/pros.21038 Filon M., Gawdzik J., Truong A., Allen G., Huang W., Khemees T., Machhi R., Lewis P., Yang B., Denu J., and Jarrard D., 2021, Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype, British Journal of Cancer, 125(2): 247-254. https://doi.org/10.1038/s41416-021-01398-7 Gelato K.A., and Fischle W., 2008, Role of histone modifications in defining chromatin structure and function, Biol. Chem., 389(4): 353-363. https://doi.org/10.1515/BC.2008.048 Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K., 2003, Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines, Molecular Cancer Therapeutics, 2(2): 151-163. Gomes A.P., Ilter D., Low V., Rosenzweig A., Shen Z.J., Schild T., Rivas M.A., Er E., McNally D., Mutvei A., Han J., Ou Y., Cavaliere P., Mullarky E., Nagiec M., Shin S., Yoon S., Dephoure N., Massagué J., Melnick A., Cantley L., Tyler J., and Blenis J., 2019, Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization, Cancer Cell, 36(4): 402-417. https://doi.org/10.1016/j.ccell.2019.08.006 Gui C.Y., Ngo L., Xu W.S., Richon V.M., and Marks P.A., 2004, Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1, Proceedings of the National Academy of Sciences of the United States of America, 101(5): 1241-1246. https://doi.org/10.1073/PNAS.0307708100 Hayashi A., Horiuchi A., Kikuchi N., Hayashi T., Fuseya C., Suzuki A., Konishi I., and Shiozawa T., 2010, Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin, International Journal of Cancer, 127(6): 1332-1346. https://doi.org/10.1002/ijc.25151 Huang H., Lin S., Garcia B., and Zhao Y., 2015, Quantitative proteomic analysis of histone modifications, Chemical Reviews, 115(6): 2376-2418. https://doi.org/10.1021/cr500491u Imamura J., Ganguly S., Muskara A., Liao R., Nguyen J., Weight C., Wee C., Gupta S., and Mian O., 2023, Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution, Frontiers in Endocrinology, 14: 1191311. https://doi.org/10.3389/fendo.2023.1191311 Jerónimo C., Bastian P.J., Bjartell A., Carbone G.M., Catto J.W.F., Clark S.J., Henrique R., Nelson W., and Shariat S., 2011, Epigenetics in prostate cancer: biologic and clinical relevance, European Urology, 60(4): 753-766. https://doi.org/10.1016/j.eururo.2011.06.035 Kelly T.K., Carvalho D.D., and Jones P.A., 2010, Epigenetic modifications as therapeutic targets, Nature Biotechnology, 28(10): 1069-1078. https://doi.org/10.1038/nbt.1678
RkJQdWJsaXNoZXIy MjQ4ODYzNA==